View Financial HealthGH Research 배당 및 자사주 매입배당 기준 점검 0/6GH Research 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.005%자사주 매입 수익률총 주주 수익률-0.005%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Dermot Hanley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • May 20GH Research: Rapid Onset And Short Action Change The Treatment ParadigmSummary GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the rapid onset and short psychedelic experience duration offered by GH001 are compelling, it remains to be seen how the drug stacks up against peers under real-world conditions. Despite this, I believe GH Research is still undervalued, largely due to the size of the market and the unmet need that exists at the moment. Read the full article on Seeking Alpha속보 • May 17GH Research Advances Depression Drug Toward Phase 3 Backed by Strong Cash and Capital MovesGH Research published Phase 2b TRD data for lead candidate GH001 in JAMA Psychiatry, reporting Day 8 remission rates between 53.9% and 63.6%. The company has selected doses for a planned global Phase 3 program targeted to start in late 2026. The company reported a Q1 2026 net loss that was wider than some analyst expectations as research, development and professional expenses related to its psychiatric pipeline increased. It maintained a cash balance of US$267.3 million as of March 31, 2026, and raised an additional US$111.2 million in April. GH Research filed an F-3 shelf to register up to US$400 million of securities and entered an at-the-market equity offering of up to US$200 million. The company also reported a 2025 net loss of US$48.3 million with an accumulated deficit of US$154.4 million, and set its 2026 AGM for June 25. The combination of positive mid-stage clinical data, an advancing late-stage trial plan and multiple capital-raising tools indicates a company focused on funding an intensive clinical program in treatment-resistant depression and related indications. Investors need to weigh the strengthened liquidity against ongoing losses, clinical and regulatory risk, potential dilution from the shelf and ATM programs, and the history of the prior FDA clinical hold that was lifted in December 2025.공시 • May 14+ 1 more updateGH Research PLC, Annual General Meeting, Jun 25, 2026GH Research PLC, Annual General Meeting, Jun 25, 2026. Location: joshua dawson house, dawson street, dublin 2, d02 ry95., Ireland공시 • May 01GH Research PLC has completed a Follow-on Equity Offering in the amount of $117.500022 million.GH Research PLC has completed a Follow-on Equity Offering in the amount of $117.500022 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,527,779 Price\Range: $18 Discount Per Security: $0.9공시 • Apr 29GH Research PLC has filed a Follow-on Equity Offering in the amount of $117.500022 million.GH Research PLC has filed a Follow-on Equity Offering in the amount of $117.500022 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,527,779 Price\Range: $18공시 • Mar 25GH Research plc Announces Publication of Phase 2B Results for Mebufotenin (Gh001) in Jama Psychiatry and Reports New Finding of Severity-Independent Efficacy in Treatment-Resistant DepressionGH Research PLC announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry, and a new analysis demonstrating that efficacy is independent of the number of prior lifetime treatment failures in a forthcoming issue of Psychopharmacology Bulletin. The peer-reviewed article, titled “GH001 vs Placebo in Patients with Treatment-Resistant Depression” has been published in JAMA Psychiatry. The publication includes the complete results from the randomized, double-blind, placebo-controlled Phase 2b trial of mebufotenin in patients with TRD, including all primary and secondary efficacy endpoints, safety and tolerability data, and initial results from the 6-month open-label extension. These results were previously reported in topline form. A supporting peer-reviewed article, titled “GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial,” will be published in a forthcoming issue of Psychopharmacology Bulletin. In TRD, a well-established finding across multiple treatment modalities is that remission rates decline significantly with each successive antidepressant treatment failure. This pattern, first quantified in the landmark STARD trial (see About STARD below), represents a fundamental challenge in treating patients with extensive treatment histories. The new analysis of Phase 2b data demonstrates that GH001 does not follow this pattern: Day 8 remission rates ranged from 53.9% to 63.6% across patients with 2 to =5 prior lifetime antidepressant failures, with no decline at higher failure counts; End of trial/Month 6 remission rates ranged from 61.5% to 85.7% across the same subgroups; and No meaningful correlation was observed between the number of prior lifetime treatment failures and Montgomery-Åsberg Depression Rating Scale (MADRS) improvement at Day 8 (r=-0.13; P=0.44) or among those who completed the 6-month OLE (r=-0.10; P=0.60). Consistent with the findings of this article, GH001 efficacy is also independent from prior treatment failures within the current depressive episode in this Phase 2b trial. Based on the observed clinical activity in our Phase 2b trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8.공시 • Jan 05Gh Research plc Announces Fda Lifts Clinical Hold on Gh001, Clearing Path for Global Phase 3 Initiation in 2026GH Research PLC announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for GH001, enabling U.S. subject enrollment and advancing alignment of the company’s development efforts across major jurisdictions. The decision follows previously reported Phase 2b trial results (GH001-TRD-201), in which GH001 met its primary endpoint with a 15.5-point placebo-adjusted reduction in MADRS score on Day 8 (p<0.0001), demonstrated ultra-rapid remission in 57.5% of patients by Day 8 and 73% remission at six months with infrequent dosing averaging approximately four treatments, showed a short psychoactive experience with a median duration of about 11 minutes, required no psychotherapy, enabled 99% of patients to be discharge-ready within one hour of dosing, and exhibited a favorable safety profile with good tolerability and no serious treatment-related adverse events. Recent presentations at scientific conferences further support GH001’s potential integration into existing interventional psychiatry practices due to its convenient administration profile.분석 기사 • Dec 11We Think GH Research (NASDAQ:GHRS) Can Easily Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Oct 17GH Research PLC Announces the Acceptance of Posters Related to its GH001-TRD-201 Clinical Trial at the 64 American College of Neuropsychopharmacology Annual MeetingGH Research PLC announced the acceptance of posters related to its GH001-TRD-201 clinical trial at the 64 American College of Neuropsychopharmacology (ACNP) annual meeting (the Congress), which is scheduled to take place from January 12-15, 2026, in Nassau, Bahamas. Over the 6-month duration of the trial, lower rates of Suicidal ideation compared to baseline were observed at each timepoint assessed with no treatment- emergent events of suicidal intent or suicidal behavior. At 99.0% (285/288) of treatment visits, patients were considered to be discharge ready at 1-hour post-dose on the dosing day. Results from a Phase 2a Clinical Trial: Results from a Phase 2a clinical trial. Over the 6-month period of the trial, lower rates the rates ofsuicidal ideation compared to baseline are observed at each timepoint assessed With GH001. At 99.0% ("285/288") of treatment visits, patients were thought to be discharge ready at 1 -hour post-dose on the Dosing day. Results from a phase 2a clinical trial. Results from a Phase 2 a clinical trial.공시 • Oct 10GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP CongressGH Research PLC announced the acceptance of a Novel Therapies Symposium Presentation at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 - 14, where Professor Wieslaw J. Cubala, MD, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, will present long-term clinical data on the safety and efficacy from the open label extension (OLE) of a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (TRD) (GH001-TRD-201). Additionally, two posters have been accepted presenting safety and tolerability data from the open-label extension part of GH001-TRD-201 as well as data on the psychoactive effects of GH001 in patients with TRD from GH001- TRD-201.분석 기사 • Aug 27We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...공시 • Jul 23GH Research plc Announces Global Pivotal Program Plans and Further Development UpdatesGH Research PLC provided updates on its business and key upcoming milestones. The company recently announced that the company submitted a complete response to the previously announced clinical hold on the Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA). The company have now received a response from the FDA with only one hold topic remaining. The FDA requested that either provide additional data or further justification related to the previously announced respiratory tract histology findings in rats. The company strongly believe, based on scientific evidence, that the respiratory tract histology findings are rat specific. There are no additional requests related to dog toxicology. There are no device related issues remaining. Engagement with FDA on IND complete response is ongoing. The company is actively working to address the remaining issue. Previously reported on the initial results from the phase 2b clinical trial of GH001 in treatment-resistant depression (TRD). This included part of the open-label extension (OLE) phase. The company can report on the full dataset. The primary endpoint was met with a highly significant placebo adjusted reduction from baseline of -15.5 points in Montgomery-Asberg Depression Rating Scale (MADRS) total score on Day 8 (p on that basis, The company expects to initiate global pivotal program in 2026.공시 • Jun 20Gh Research Submits Complete Ind Hold Response to FDA Ahead of ScheduleGH Research PLC announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to the U.S. Food and Drug Administration (FDA).공시 • Jun 19GH Research PLC, Annual General Meeting, Jul 31, 2025GH Research PLC, Annual General Meeting, Jul 31, 2025. Location: joshua dawson house, dawson street, dublin 2, d02 ry95, Ireland분석 기사 • May 10We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Feb 06GH Research PLC has completed a Follow-on Equity Offering in the amount of $150 million.GH Research PLC has completed a Follow-on Equity Offering in the amount of $150 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: $15 Discount Per Security: $0.9공시 • Feb 04+ 1 more updateGH Research PLC has filed a Follow-on Equity Offering in the amount of $150 million.GH Research PLC has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Ordinary Shares Security Type: Common Stock분석 기사 • Jan 31We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...공시 • Jan 11GH Research PLC Provides Updates on Its Business and Highlighted Key Upcoming MilestonesGH Research PLC provided updates on its business and highlighted key upcoming milestones. The primary endpoint of the Phase 2a proof-of-concept (POC) trial for GH001 in postpartum depression (PPD) was met with a significant reduction from baseline of 35.4 points (96.3%) in Montgomery sberg Depression Rating Scale (MADRS) total score on Day 8 after administration of GH001 (p<0.0001). On Day 8, 100% of patients were in remission (MADRS 10). GH001 led to an ultra-rapid antidepressant effect with a significant reduction in MADRS score at 2 hours after administration of 31.4 points (p<0.0001) and on Day 2 of 36.0 points (p<0.0001). The trial recruited 10 patients with PPD. All patients were administered an individualized dosing regimen (IDR) of up to three escalating doses of GH001. There was no psychotherapeutic intervention in this trial. The mean total MADRS score on Day 8 was 1.3 and all 10 patients were in remission. GH001 was well tolerated and no treatment-related serious adverse events were reported. All treatment-emergent adverse events (TEAEs) were mild or moderate. The primary endpoint of the Phase 2a POC trial for GH001 in bipolar II disorder with a current major depressive episode (BDII) was met with a significant reduction from baseline of 16.8 points (51.9%) in MADRS total score on Day 8 after administration of GH001 (p=0.0099). On Day 8, 33.3% of patients were in remission (MADRS 10). GH001 led to an ultra-rapid antidepressant effect with a reduction in MADRS score at 2 hours after administration of 16.3 points (p=0.0006) and on Day 2 of -13.3 points (p=0.0299). The trial recruited 6 patients with BDII. All patients were administered an IDR of up to three escalating doses of GH001. There was no psychotherapeutic intervention in this trial. GH001 was well tolerated and no treatment-related serious adverse events were reported. The majority of TEAEs were mild or moderate and there were no reported TEAEs of hypomania or mania. Update on IND for GH001 As previously announced, Investigational New Drug Application (IND) for GH001 administered using proprietary aerosol delivery device has been placed on clinical hold by the U.S. Food and Drug Administration (FDA), with the FDA requesting that the company provide (i) an inhalation toxicology study in a non-rodent species and an additional inhalation toxicology study in rats, (ii) additional device design verification information and (iii) updates to investigator brochure, to resolve the hold. The requested additional inhalation toxicology study in a non-rodent species has now been completed. The pathology report concludes that there are no histology findings in the respiratory tract of any dogs at any dose level evaluated in the study. Based on previously announced FDA interactions, the response to their request for additional device design verification information is being prepared and, together with the completion of the inhalation toxicology studies, provides the final piece of information requested by the agency. This trial also includes a 6-month open-label extension which is on track for completion of last patient visit in the first quarter of 2025.분석 기사 • Oct 11We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Sep 03GH Research PLC Announces Chief Executive Officer ChangesGH Research PLC announced the promotion of Dr. Velichka “Villy” Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company’s Chief Medical Officer since February 2024 having leadership responsibility, among other things, for the execution of the Company’s clinical development programs. She joined from Albireo, where, in her position as VP and Head of Medical Affairs International, she played a pivotal role in the company’s late-stage development, scientific communication, regulatory approvals by the U.S. Food and Drug Administration and EMA as well as gaining market access in multiple markets of the rare disease medicine Bylvay. Dr. Valcheva holds a Masters in Pharmaceutical Medicine from Trinity College Dublin, Ireland as well as a Dr. Med. from University of Medicine – Plovdiv, Bulgaria.분석 기사 • Jun 21We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • May 18GH Research PLC, Annual General Meeting, Jun 27, 2024GH Research PLC, Annual General Meeting, Jun 27, 2024. Location: joshua dawson house, dawson street dublin 2, d02 ry95, IrelandPrice Target Changed • Mar 03Price target decreased by 12% to US$31.75Down from US$36.25, the current price target is an average from 4 analysts. New target price is 274% above last closing price of US$8.50. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$1.05 next year compared to a net loss per share of US$0.68 last year.분석 기사 • Mar 01GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...Price Target Changed • Dec 18Price target decreased by 11% to US$34.50Down from US$38.75, the current price target is an average from 4 analysts. New target price is 556% above last closing price of US$5.26. Stock is down 44% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$0.43 last year.분석 기사 • Nov 17GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...공시 • Oct 01GH Research PLC Provides Updates and Guidance on Its Clinical Development Program for GH001 in Treatment-Resistant DepressionGH Research PLC provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD). Development Strategy: As previously announced, following successful completion of Phase 1/2 trial of GH001 in patients with TRD (GH001-TRD-102), company is recruiting for a European multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in patients with TRD (GH001-TRD-201), where GH001 is administered using an externally-sourced inhalation device. Separately, company submitted, in the third quarter of 2023, an Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA), with the purpose to initiate a Phase 1 healthy volunteer clinical pharmacology trial, where GH001 is administered using proprietary aerosol delivery device (GH001-HV-106). The trial, subject to regulatory clearance from the FDA, is designed to support bridging to the clinical data generated with the externally-sourced inhalation device company currently use in European Phase 2b trial such that company can initiate, subject to data and regulatory clearance, a subsequent global Phase 3 pivotal program using proprietary device. Update and Guidance on European Phase 2b Clinical Trial of GH001 in Patients with TRD: Company multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in patients with TRD (GH001-TRD-201) is now approved in seven European countries and is expected to recruit approximately 80 patients across approximately 20 sites. The primary objective of the trial is to determine the efficacy of single-day individualized dosing regimen (IDR) of GH001 compared with placebo in improving depressive symptoms as assessed by the mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) at the end of the 7-day double-blind phase. The double-blind phase is followed by a 6-month open-label extension phase where all patients can receive treatment with the GH001 IDR as-needed, based on the patient’s clinical status. With 14 sites initiated and additional site initiations scheduled, Company is now in a position to provide guidance on completion of the double-blind phase of this trial, which is expected to occur in the third quarter of 2024, with top-line data available in the third or the fourth quarter of 2024. Update on IND for GH001: The Company recently submitted an IND for GH001 with the FDA. At the end of the 30-day review period, the FDA advised that it had placed IND on clinical hold due to “21 CFR 312.42(b)(1)(iv): Insufficient information to assess risks to human subjects”. The FDA indicated that a letter with additional details will be issued within 30 days.분석 기사 • Jul 30GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Jul 22GH Research PLC, Annual General Meeting, Aug 31, 2023GH Research PLC, Annual General Meeting, Aug 31, 2023, at 09:00 US Eastern Standard Time. Location: Joshua Dawson House Dawson Street Dublin 2 Co. Dublin Ireland Agenda: To re-elect, by separate resolutions, the individuals who retire as directors in accordance with the Constitution of the Company and, being eligible, offer themselves for re-election; to ratify the appointment of PricewaterhouseCoopers Ireland as independent auditors of the Company for the year ending 31 December 2023 and to authorize the Board to fix the remuneration of the auditors; to review the affairs of the Company and consider the Irish statutory financial statements for the year ended 31 December 2022 and the reports of the directors and auditors thereon; and to transact such other business as may properly come before the AGM or any adjournment or postponement thereof.공시 • May 26Gh Research plc Announces Accepted for Publication in Frontiers in PsychiatryOn May 23, 2023, GH Research PLC announced a manuscript titled "A Phase 1/2 Trial to Assess Safety and Efficacy of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Patients with Treatment-Resistant Depression" was accepted for publication in Frontiers in Psychiatry. The manuscript describes the results of completed phase 1/2 clinical trial in patients with treatment-resistant depression (GH001-TRD-102, NCT04698603). The abstract is available on the publisher's website. The final, formatted version of the manuscript will be published in due course.분석 기사 • Mar 13We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Nov 28Companies Like GH Research (NASDAQ:GHRS) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Vice Chairman Michael Forer was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Seeking Alpha • Aug 23GH Research GAAP EPS of $0.006GH Research press release (NASDAQ:GHRS): Q2 GAAP EPS of $0.006. Cash was $265.4 million as of June 30, 2022, compared to $276.8 million as of December 31, 2021. The company believes that existing cash will be sufficient to fund operating expenses and capital expenditure requirements into 2025.분석 기사 • Aug 15We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Apr 29GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Vice Chairman Michael Forer was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Jan 13We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...분석 기사 • Sep 30GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Aug 15GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot IndustryThe WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June. Investing in biotech may be the way to go for investors looking for large gains over the long term.공시 • Jun 26GH Research PLC has completed an IPO in the amount of $160 million.GH Research PLC has completed an IPO in the amount of $160 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: $16지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GHRS 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GHRS 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장GH Research 배당 수익률 vs 시장GHRS의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GHRS)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (GHRS) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GHRS 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GHRS 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GHRS 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GHRS 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 15:21종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GH Research PLC는 11명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sumant Satchidanand KulkarniCanaccord GenuityCharles DuncanCantor Fitzgerald & Co.Joshua SchimmerCantor Fitzgerald & Co.8명의 분석가 더 보기
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Dermot Hanley was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • May 20GH Research: Rapid Onset And Short Action Change The Treatment ParadigmSummary GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the rapid onset and short psychedelic experience duration offered by GH001 are compelling, it remains to be seen how the drug stacks up against peers under real-world conditions. Despite this, I believe GH Research is still undervalued, largely due to the size of the market and the unmet need that exists at the moment. Read the full article on Seeking Alpha
속보 • May 17GH Research Advances Depression Drug Toward Phase 3 Backed by Strong Cash and Capital MovesGH Research published Phase 2b TRD data for lead candidate GH001 in JAMA Psychiatry, reporting Day 8 remission rates between 53.9% and 63.6%. The company has selected doses for a planned global Phase 3 program targeted to start in late 2026. The company reported a Q1 2026 net loss that was wider than some analyst expectations as research, development and professional expenses related to its psychiatric pipeline increased. It maintained a cash balance of US$267.3 million as of March 31, 2026, and raised an additional US$111.2 million in April. GH Research filed an F-3 shelf to register up to US$400 million of securities and entered an at-the-market equity offering of up to US$200 million. The company also reported a 2025 net loss of US$48.3 million with an accumulated deficit of US$154.4 million, and set its 2026 AGM for June 25. The combination of positive mid-stage clinical data, an advancing late-stage trial plan and multiple capital-raising tools indicates a company focused on funding an intensive clinical program in treatment-resistant depression and related indications. Investors need to weigh the strengthened liquidity against ongoing losses, clinical and regulatory risk, potential dilution from the shelf and ATM programs, and the history of the prior FDA clinical hold that was lifted in December 2025.
공시 • May 14+ 1 more updateGH Research PLC, Annual General Meeting, Jun 25, 2026GH Research PLC, Annual General Meeting, Jun 25, 2026. Location: joshua dawson house, dawson street, dublin 2, d02 ry95., Ireland
공시 • May 01GH Research PLC has completed a Follow-on Equity Offering in the amount of $117.500022 million.GH Research PLC has completed a Follow-on Equity Offering in the amount of $117.500022 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,527,779 Price\Range: $18 Discount Per Security: $0.9
공시 • Apr 29GH Research PLC has filed a Follow-on Equity Offering in the amount of $117.500022 million.GH Research PLC has filed a Follow-on Equity Offering in the amount of $117.500022 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 6,527,779 Price\Range: $18
공시 • Mar 25GH Research plc Announces Publication of Phase 2B Results for Mebufotenin (Gh001) in Jama Psychiatry and Reports New Finding of Severity-Independent Efficacy in Treatment-Resistant DepressionGH Research PLC announced two peer-reviewed publications from its Phase 2b clinical program of GH001 in treatment-resistant depression (TRD): the primary trial results in JAMA Psychiatry, and a new analysis demonstrating that efficacy is independent of the number of prior lifetime treatment failures in a forthcoming issue of Psychopharmacology Bulletin. The peer-reviewed article, titled “GH001 vs Placebo in Patients with Treatment-Resistant Depression” has been published in JAMA Psychiatry. The publication includes the complete results from the randomized, double-blind, placebo-controlled Phase 2b trial of mebufotenin in patients with TRD, including all primary and secondary efficacy endpoints, safety and tolerability data, and initial results from the 6-month open-label extension. These results were previously reported in topline form. A supporting peer-reviewed article, titled “GH001 Efficacy is Independent of Prior Antidepressant Treatment Failures in Treatment-Resistant Depression: A Post Hoc Analysis of a Phase 2b Randomized Controlled Trial,” will be published in a forthcoming issue of Psychopharmacology Bulletin. In TRD, a well-established finding across multiple treatment modalities is that remission rates decline significantly with each successive antidepressant treatment failure. This pattern, first quantified in the landmark STARD trial (see About STARD below), represents a fundamental challenge in treating patients with extensive treatment histories. The new analysis of Phase 2b data demonstrates that GH001 does not follow this pattern: Day 8 remission rates ranged from 53.9% to 63.6% across patients with 2 to =5 prior lifetime antidepressant failures, with no decline at higher failure counts; End of trial/Month 6 remission rates ranged from 61.5% to 85.7% across the same subgroups; and No meaningful correlation was observed between the number of prior lifetime treatment failures and Montgomery-Åsberg Depression Rating Scale (MADRS) improvement at Day 8 (r=-0.13; P=0.44) or among those who completed the 6-month OLE (r=-0.10; P=0.60). Consistent with the findings of this article, GH001 efficacy is also independent from prior treatment failures within the current depressive episode in this Phase 2b trial. Based on the observed clinical activity in our Phase 2b trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8.
공시 • Jan 05Gh Research plc Announces Fda Lifts Clinical Hold on Gh001, Clearing Path for Global Phase 3 Initiation in 2026GH Research PLC announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug (IND) application for GH001, enabling U.S. subject enrollment and advancing alignment of the company’s development efforts across major jurisdictions. The decision follows previously reported Phase 2b trial results (GH001-TRD-201), in which GH001 met its primary endpoint with a 15.5-point placebo-adjusted reduction in MADRS score on Day 8 (p<0.0001), demonstrated ultra-rapid remission in 57.5% of patients by Day 8 and 73% remission at six months with infrequent dosing averaging approximately four treatments, showed a short psychoactive experience with a median duration of about 11 minutes, required no psychotherapy, enabled 99% of patients to be discharge-ready within one hour of dosing, and exhibited a favorable safety profile with good tolerability and no serious treatment-related adverse events. Recent presentations at scientific conferences further support GH001’s potential integration into existing interventional psychiatry practices due to its convenient administration profile.
분석 기사 • Dec 11We Think GH Research (NASDAQ:GHRS) Can Easily Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Oct 17GH Research PLC Announces the Acceptance of Posters Related to its GH001-TRD-201 Clinical Trial at the 64 American College of Neuropsychopharmacology Annual MeetingGH Research PLC announced the acceptance of posters related to its GH001-TRD-201 clinical trial at the 64 American College of Neuropsychopharmacology (ACNP) annual meeting (the Congress), which is scheduled to take place from January 12-15, 2026, in Nassau, Bahamas. Over the 6-month duration of the trial, lower rates of Suicidal ideation compared to baseline were observed at each timepoint assessed with no treatment- emergent events of suicidal intent or suicidal behavior. At 99.0% (285/288) of treatment visits, patients were considered to be discharge ready at 1-hour post-dose on the dosing day. Results from a Phase 2a Clinical Trial: Results from a Phase 2a clinical trial. Over the 6-month period of the trial, lower rates the rates ofsuicidal ideation compared to baseline are observed at each timepoint assessed With GH001. At 99.0% ("285/288") of treatment visits, patients were thought to be discharge ready at 1 -hour post-dose on the Dosing day. Results from a phase 2a clinical trial. Results from a Phase 2 a clinical trial.
공시 • Oct 10GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP CongressGH Research PLC announced the acceptance of a Novel Therapies Symposium Presentation at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 - 14, where Professor Wieslaw J. Cubala, MD, PhD, Department of Psychiatry, Faculty of Medicine, Medical University of Gdansk, will present long-term clinical data on the safety and efficacy from the open label extension (OLE) of a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001 in patients with treatment-resistant depression (TRD) (GH001-TRD-201). Additionally, two posters have been accepted presenting safety and tolerability data from the open-label extension part of GH001-TRD-201 as well as data on the psychoactive effects of GH001 in patients with TRD from GH001- TRD-201.
분석 기사 • Aug 27We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
공시 • Jul 23GH Research plc Announces Global Pivotal Program Plans and Further Development UpdatesGH Research PLC provided updates on its business and key upcoming milestones. The company recently announced that the company submitted a complete response to the previously announced clinical hold on the Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA). The company have now received a response from the FDA with only one hold topic remaining. The FDA requested that either provide additional data or further justification related to the previously announced respiratory tract histology findings in rats. The company strongly believe, based on scientific evidence, that the respiratory tract histology findings are rat specific. There are no additional requests related to dog toxicology. There are no device related issues remaining. Engagement with FDA on IND complete response is ongoing. The company is actively working to address the remaining issue. Previously reported on the initial results from the phase 2b clinical trial of GH001 in treatment-resistant depression (TRD). This included part of the open-label extension (OLE) phase. The company can report on the full dataset. The primary endpoint was met with a highly significant placebo adjusted reduction from baseline of -15.5 points in Montgomery-Asberg Depression Rating Scale (MADRS) total score on Day 8 (p on that basis, The company expects to initiate global pivotal program in 2026.
공시 • Jun 20Gh Research Submits Complete Ind Hold Response to FDA Ahead of ScheduleGH Research PLC announced that, in June, it submitted its complete response to the previously announced clinical hold of its Investigational New Drug Application (IND) for GH001 to the U.S. Food and Drug Administration (FDA).
공시 • Jun 19GH Research PLC, Annual General Meeting, Jul 31, 2025GH Research PLC, Annual General Meeting, Jul 31, 2025. Location: joshua dawson house, dawson street, dublin 2, d02 ry95, Ireland
분석 기사 • May 10We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Feb 06GH Research PLC has completed a Follow-on Equity Offering in the amount of $150 million.GH Research PLC has completed a Follow-on Equity Offering in the amount of $150 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: $15 Discount Per Security: $0.9
공시 • Feb 04+ 1 more updateGH Research PLC has filed a Follow-on Equity Offering in the amount of $150 million.GH Research PLC has filed a Follow-on Equity Offering in the amount of $150 million. Security Name: Ordinary Shares Security Type: Common Stock
분석 기사 • Jan 31We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, although...
공시 • Jan 11GH Research PLC Provides Updates on Its Business and Highlighted Key Upcoming MilestonesGH Research PLC provided updates on its business and highlighted key upcoming milestones. The primary endpoint of the Phase 2a proof-of-concept (POC) trial for GH001 in postpartum depression (PPD) was met with a significant reduction from baseline of 35.4 points (96.3%) in Montgomery sberg Depression Rating Scale (MADRS) total score on Day 8 after administration of GH001 (p<0.0001). On Day 8, 100% of patients were in remission (MADRS 10). GH001 led to an ultra-rapid antidepressant effect with a significant reduction in MADRS score at 2 hours after administration of 31.4 points (p<0.0001) and on Day 2 of 36.0 points (p<0.0001). The trial recruited 10 patients with PPD. All patients were administered an individualized dosing regimen (IDR) of up to three escalating doses of GH001. There was no psychotherapeutic intervention in this trial. The mean total MADRS score on Day 8 was 1.3 and all 10 patients were in remission. GH001 was well tolerated and no treatment-related serious adverse events were reported. All treatment-emergent adverse events (TEAEs) were mild or moderate. The primary endpoint of the Phase 2a POC trial for GH001 in bipolar II disorder with a current major depressive episode (BDII) was met with a significant reduction from baseline of 16.8 points (51.9%) in MADRS total score on Day 8 after administration of GH001 (p=0.0099). On Day 8, 33.3% of patients were in remission (MADRS 10). GH001 led to an ultra-rapid antidepressant effect with a reduction in MADRS score at 2 hours after administration of 16.3 points (p=0.0006) and on Day 2 of -13.3 points (p=0.0299). The trial recruited 6 patients with BDII. All patients were administered an IDR of up to three escalating doses of GH001. There was no psychotherapeutic intervention in this trial. GH001 was well tolerated and no treatment-related serious adverse events were reported. The majority of TEAEs were mild or moderate and there were no reported TEAEs of hypomania or mania. Update on IND for GH001 As previously announced, Investigational New Drug Application (IND) for GH001 administered using proprietary aerosol delivery device has been placed on clinical hold by the U.S. Food and Drug Administration (FDA), with the FDA requesting that the company provide (i) an inhalation toxicology study in a non-rodent species and an additional inhalation toxicology study in rats, (ii) additional device design verification information and (iii) updates to investigator brochure, to resolve the hold. The requested additional inhalation toxicology study in a non-rodent species has now been completed. The pathology report concludes that there are no histology findings in the respiratory tract of any dogs at any dose level evaluated in the study. Based on previously announced FDA interactions, the response to their request for additional device design verification information is being prepared and, together with the completion of the inhalation toxicology studies, provides the final piece of information requested by the agency. This trial also includes a 6-month open-label extension which is on track for completion of last patient visit in the first quarter of 2025.
분석 기사 • Oct 11We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Sep 03GH Research PLC Announces Chief Executive Officer ChangesGH Research PLC announced the promotion of Dr. Velichka “Villy” Valcheva, MD, MSc. to Chief Executive Officer of the Company. Dr. Valcheva succeeds PD Dr. med. Theis Terwey, co-founder of GH Research. Dr. Valcheva has more than 20 years of experience in various leadership roles in the pharmaceutical and biotech industries. Dr. Valcheva joined the company in August 2023 and has served as the Company’s Chief Medical Officer since February 2024 having leadership responsibility, among other things, for the execution of the Company’s clinical development programs. She joined from Albireo, where, in her position as VP and Head of Medical Affairs International, she played a pivotal role in the company’s late-stage development, scientific communication, regulatory approvals by the U.S. Food and Drug Administration and EMA as well as gaining market access in multiple markets of the rare disease medicine Bylvay. Dr. Valcheva holds a Masters in Pharmaceutical Medicine from Trinity College Dublin, Ireland as well as a Dr. Med. from University of Medicine – Plovdiv, Bulgaria.
분석 기사 • Jun 21We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • May 18GH Research PLC, Annual General Meeting, Jun 27, 2024GH Research PLC, Annual General Meeting, Jun 27, 2024. Location: joshua dawson house, dawson street dublin 2, d02 ry95, Ireland
Price Target Changed • Mar 03Price target decreased by 12% to US$31.75Down from US$36.25, the current price target is an average from 4 analysts. New target price is 274% above last closing price of US$8.50. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$1.05 next year compared to a net loss per share of US$0.68 last year.
분석 기사 • Mar 01GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Price Target Changed • Dec 18Price target decreased by 11% to US$34.50Down from US$38.75, the current price target is an average from 4 analysts. New target price is 556% above last closing price of US$5.26. Stock is down 44% over the past year. The company is forecast to post a net loss per share of US$0.67 next year compared to a net loss per share of US$0.43 last year.
분석 기사 • Nov 17GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
공시 • Oct 01GH Research PLC Provides Updates and Guidance on Its Clinical Development Program for GH001 in Treatment-Resistant DepressionGH Research PLC provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD). Development Strategy: As previously announced, following successful completion of Phase 1/2 trial of GH001 in patients with TRD (GH001-TRD-102), company is recruiting for a European multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in patients with TRD (GH001-TRD-201), where GH001 is administered using an externally-sourced inhalation device. Separately, company submitted, in the third quarter of 2023, an Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA), with the purpose to initiate a Phase 1 healthy volunteer clinical pharmacology trial, where GH001 is administered using proprietary aerosol delivery device (GH001-HV-106). The trial, subject to regulatory clearance from the FDA, is designed to support bridging to the clinical data generated with the externally-sourced inhalation device company currently use in European Phase 2b trial such that company can initiate, subject to data and regulatory clearance, a subsequent global Phase 3 pivotal program using proprietary device. Update and Guidance on European Phase 2b Clinical Trial of GH001 in Patients with TRD: Company multi-center, randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in patients with TRD (GH001-TRD-201) is now approved in seven European countries and is expected to recruit approximately 80 patients across approximately 20 sites. The primary objective of the trial is to determine the efficacy of single-day individualized dosing regimen (IDR) of GH001 compared with placebo in improving depressive symptoms as assessed by the mean change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) at the end of the 7-day double-blind phase. The double-blind phase is followed by a 6-month open-label extension phase where all patients can receive treatment with the GH001 IDR as-needed, based on the patient’s clinical status. With 14 sites initiated and additional site initiations scheduled, Company is now in a position to provide guidance on completion of the double-blind phase of this trial, which is expected to occur in the third quarter of 2024, with top-line data available in the third or the fourth quarter of 2024. Update on IND for GH001: The Company recently submitted an IND for GH001 with the FDA. At the end of the 30-day review period, the FDA advised that it had placed IND on clinical hold due to “21 CFR 312.42(b)(1)(iv): Insufficient information to assess risks to human subjects”. The FDA indicated that a letter with additional details will be issued within 30 days.
분석 기사 • Jul 30GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Jul 22GH Research PLC, Annual General Meeting, Aug 31, 2023GH Research PLC, Annual General Meeting, Aug 31, 2023, at 09:00 US Eastern Standard Time. Location: Joshua Dawson House Dawson Street Dublin 2 Co. Dublin Ireland Agenda: To re-elect, by separate resolutions, the individuals who retire as directors in accordance with the Constitution of the Company and, being eligible, offer themselves for re-election; to ratify the appointment of PricewaterhouseCoopers Ireland as independent auditors of the Company for the year ending 31 December 2023 and to authorize the Board to fix the remuneration of the auditors; to review the affairs of the Company and consider the Irish statutory financial statements for the year ended 31 December 2022 and the reports of the directors and auditors thereon; and to transact such other business as may properly come before the AGM or any adjournment or postponement thereof.
공시 • May 26Gh Research plc Announces Accepted for Publication in Frontiers in PsychiatryOn May 23, 2023, GH Research PLC announced a manuscript titled "A Phase 1/2 Trial to Assess Safety and Efficacy of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Patients with Treatment-Resistant Depression" was accepted for publication in Frontiers in Psychiatry. The manuscript describes the results of completed phase 1/2 clinical trial in patients with treatment-resistant depression (GH001-TRD-102, NCT04698603). The abstract is available on the publisher's website. The final, formatted version of the manuscript will be published in due course.
분석 기사 • Mar 13We're Hopeful That GH Research (NASDAQ:GHRS) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Nov 28Companies Like GH Research (NASDAQ:GHRS) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Vice Chairman Michael Forer was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Aug 23GH Research GAAP EPS of $0.006GH Research press release (NASDAQ:GHRS): Q2 GAAP EPS of $0.006. Cash was $265.4 million as of June 30, 2022, compared to $276.8 million as of December 31, 2021. The company believes that existing cash will be sufficient to fund operating expenses and capital expenditure requirements into 2025.
분석 기사 • Aug 15We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
분석 기사 • Apr 29GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Vice Chairman Michael Forer was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Jan 13We're Not Very Worried About GH Research's (NASDAQ:GHRS) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
분석 기사 • Sep 30GH Research (NASDAQ:GHRS) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 15GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot IndustryThe WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June. Investing in biotech may be the way to go for investors looking for large gains over the long term.
공시 • Jun 26GH Research PLC has completed an IPO in the amount of $160 million.GH Research PLC has completed an IPO in the amount of $160 million. Security Name: Ordinary shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: $16